DR. BOBBY V KHAN, M.D.
Osteopathic Medicine at Peachtree Dunwoody Rd, Atlanta, GA
License number
Georgia 37251
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
2
5673 Peachtree Dunwoody Rd SUITE 440, Atlanta, GA 30342
145 Travertine Trl, Alpharetta, GA 30022
145 Travertine Trl, Alpharetta, GA 30022
Phone
(404) 296-1130
(404) 600-4466 (Fax)
(404) 600-4466 (Fax)
Personal information
See more information about BOBBY V KHAN at radaris.comName
Address
Phone
145 Travertine Trl, Alpharetta, GA 30022
5559 Glenridge Dr NE APT 1201, Atlanta, GA 30342
145 Travertine Trl, Alpharetta, GA 30022
1717 Decatur St, Atlanta, GA 30322
175 Country Club Dr, Stockbridge, GA 30281
Professional information
Dr. Bobby V Khan, Atlanta GA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
Atlanta Cardiology/Primary Care
5673 Peachtree Dunwoody Rd SUITE 44, Atlanta 30342
(404) 296-1130 (Phone)
5673 Peachtree Dunwoody Rd SUITE 44, Atlanta 30342
(404) 296-1130 (Phone)
Certifications:
Internal Medicine, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Atlanta Cardiology/Primary Care
5673 Peachtree Dunwoody Rd SUITE 44, Atlanta 30342
Emory University Hospital Midtown
550 Peachtree St North #East, Atlanta 30308
Saint Joseph's Hospital of Atlanta
5665 Peachtree Dunwoody Rd North #East, Atlanta 30342
5673 Peachtree Dunwoody Rd SUITE 44, Atlanta 30342
Emory University Hospital Midtown
550 Peachtree St North #East, Atlanta 30308
Saint Joseph's Hospital of Atlanta
5665 Peachtree Dunwoody Rd North #East, Atlanta 30342
Education:
Medical School
University of Tennessee / Memphis / College of Medicine & Surgery
Graduated: 1990
UCLA Mc
Emory University School Of Medicine
University of Tennessee / Memphis / College of Medicine & Surgery
Graduated: 1990
UCLA Mc
Emory University School Of Medicine
Executive Director, Carmel Biosciences
Position:
Executive Director at Carmel Biosciences, Professor of Internal Medicine at University of Central Florida, Executive Director and Chief Scientific Officer at Atlanta Vascular Research Foundation, Clinical Translational Research at Saint Joseph's Translational Research Institute
Location:
Greater Atlanta Area
Industry:
Research
Work:
Carmel Biosciences
- Atlanta, Georgia since Jan 2011
-
Executive Director
University of Central Florida
- Orlando, Florida Area since Sep 2012
-
Professor of Internal Medicine
Atlanta Vascular Research Foundation
since Sep 2012
-
Executive Director and Chief Scientific Officer
Saint Joseph's Translational Research Institute
since Oct 2009
-
Clinical Translational Research
Emory University
Sep 2001 - Sep 2009
-
Director, Coronary Care Unit and Cardiovascular Research
Education:
University of Tennessee-Health Science Center College of Medicine 1984 - 1990
MD, PhD
MD, PhD
Bobby Khan, Atlanta GA
Specialties:
General Practice, Internal Medicine, Cardiovascular Disease, Cardiology
Work:
Atlanta Cardiology & Primary Care
5673 Peachtree Dunwoody Rd NE, Atlanta, GA 30342 Atlanta Cardio & Primary Care
3562 Habers Northlk, Tucker, GA 30084
5673 Peachtree Dunwoody Rd NE, Atlanta, GA 30342 Atlanta Cardio & Primary Care
3562 Habers Northlk, Tucker, GA 30084
Education:
University of Tennessee (1990)
President At Invasc Therapeutics
Position:
President at InVasc Therapeutics
Location:
Greater Atlanta Area
Industry:
Medical Practice
Work:
InVasc Therapeutics
-
President
Treatment For Atherosclerosis And Other Cardiovascular And Inflammatory Diseases
US Patent:
5811449, Sep 22, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/483335
Inventors:
Russell M. Medford - Atlanta GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
Assignee:
Emory University - Altanta GA
International Classification:
A61K 3140, A61K 3154, A61K 31265, A61K 31185
US Classification:
514423
Abstract:
A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.
Treatment For Atherosclerosis And Other Cardiovascular And Inflammatory Diseases
US Patent:
5750351, May 12, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/474530
Inventors:
Russell M. Medford - Atlanta GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
Assignee:
Emory University - Atlanta GA
International Classification:
G01N 3353, A61K 3140, A61K 3154, A61K 31265
US Classification:
435 721
Abstract:
A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.
Treatment For Atherosclerosis And Other Cardiovascular And Inflammatory Diseases
US Patent:
5773231, Jun 30, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/473272
Inventors:
Russell M. Medford - Atlanta GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
Assignee:
Emory University - Atlanta GA
International Classification:
G01N 3353
US Classification:
435 724
Abstract:
A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.
Treatment For Atherosclerosis And Other Cardiovascular And Inflammatory Diseases
US Patent:
5807884, Sep 15, 1998
Filed:
Oct 4, 1994
Appl. No.:
8/317399
Inventors:
Russell M. Medford - Atlanta GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
Assignee:
Emory University - Atlanta GA
International Classification:
A61K 3140, A61K 3154, A61K 31265, A61K 31185
US Classification:
514423
Abstract:
A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.
Treatment For Atherosclerosis And Other Cardiovascular And Inflammatory Diseases
US Patent:
5846959, Dec 8, 1998
Filed:
Jun 6, 1995
Appl. No.:
8/471537
Inventors:
Russell M. Medford - Atlanta GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
Assignee:
Emory University - Atlanta GA
International Classification:
A61K 3160, A61K 3156, A61K 3140, A61K 3137
US Classification:
514165
Abstract:
A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.
Treatment For Atherosclerosis And Other Cardiovascular And Inflammatory Diseases
US Patent:
5773209, Jun 30, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/484059
Inventors:
Russell M. Medford - Atlanta GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
R. Wayne Alexander - Atlanta GA
Sampath Parthasarathy - Atlanta GA
Bobby V. Khan - Dunwoody GA
Assignee:
Emory University - Atlanta GA
International Classification:
G01N 3353
US Classification:
435 724
Abstract:
A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.